Table 1.
Baseline demographic and baseline and follow-up disease characteristics.
| Characteristics | n: 48 | |
|---|---|---|
| Baseline age, years, mean (SD) | 33.0 (10.5) | |
| Female, n (%) | 34 (71%) | |
| Mean disease duration of RRMS since diagnosis (SD), years | 1.7 (1.4) | |
| Expanded Disability Status Scale score, mean (range), baseline and follow-up | 1.3 (0–4) | 1.3 (0–4.5) |
| Brief International Cognitive Assessment for Multiple Sclerosis, mean (SD), baseline and follow-up | 121 (25) | 125 (29) |
| Symbol Digit Modalities Test | 43.5 (13) | 45.3 (12) |
| California Verbal Learning Test 2 | 54.3 (10) | 54.4 (12) |
| Brief Visual Spatial Memory Test-Revised | 23.9 (7) | 25.3 (7) |
| Disease-modifying therapy, n (%), baseline and follow-up | ||
| Interferon | 22 (44) | 13 (27) |
| Fingolimod | 16 (34) | 23 (44) |
| Glatiramer acetate | 8 (15) | 8 (17) |
| Teriflunomide | 2 (4) | 2 (4) |
| Natalizumab | 0 | 1 (2) |
| Alemtuzumab | 0 | 1 (2) |
| Relapses before 1st visit, n (%) one | 31 (65%) | |
| two or more | 17 (35%) | |
| T2 lesions, n (%), baseline and follow-up. <10 | 16 (33%) | 7 (15%) |
| 11–50 | 30 (60%) | 27 (56%) |
| >50 | 2 (6.4%) | 12 (25%) |
| Gadolinium-enhanced T1 lesions, n (%), baseline and follow-up. | 9 (19%) | 5 (10%) |
| Proportion of patients who failed to meet NEDA-4 criteria | ||
| Relapses | 21% (10/48) | |
| EDSS progression | 21% (10/48) | |
| New T2 lesions | 8% (4/48) | |
| Gadolinium-enhanced T1 lesions | 10% (5/48) | |
| a-BVL >0.4% | 52% (25/48) | |
| Proportion of patients achieving NEDA-3 status | 58% (28/48) | |
| Proportion of patients achieving NEDA-4 status | 29% (14/48) | |
RRMS, relapsing-remitting multiple sclerosis; EDSS, Expanded Disability Status Scale; a-BVL, annualized brain volume loss; NEDA, no evidence of disease activity.